Methods of treating a diabetic embryopathy
AssigneeUniversity of Maryland, Baltimore
InventorsE. Albert Reece, Zhiyong Zhao, Peixin Yang
Life of this patent
Estimating the term…
Abstract
Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods of treating a diabetic embryopathy.
Claims10
A method of treating a diabetic embryopathy comprising:
- administering to a pregnant mammal carrying an embryo or fetus having said embryopathy, an effective amount of at least one agent that modulates the activity of apoptosis signal-regulating kinase 1 (ASK1),
- wherein the at least one agent comprises at least one ASK1 inhibitor selected from the group consisting of thioredoxin;
- thioredoxin reductase;
- caspase-activated DNase (CAD) inhibitor;
- glutathione S-transferase mu;
- and an antagonist anti-ASK1 antibody.
A method of treating a diabetic embryopathy comprising administering to a pregnant mammal carrying an embryo or fetus having said embryopathy, an effective amount of at least one agent that modulates activity of a polypeptide involved in cell signaling that is altered during maternal diabetes or participates in the pathology of a diabetic embryopathy,
- wherein the at least one agent comprises at least one ASK1 inhibitor selected from the group consisting of thioredoxin;
- thioredoxin reductase;
- caspase-activated DNase (CAD) inhibitor;
- glutathione S-transferase mu;
- and an antagonist anti-ASK1 antibody.
A method of treating a diabetic embryopathy comprising administering to a pregnant mammal carrying an embryo or fetus having said embryopathy, an effective amount of at least one agent that modulates activity of ASK, wherein the at least one agent comprises at least one ASK1 inhibitor selected from the group consisting of thioredoxin;
- thioredoxin reductase;
- caspase-activated DNase (CAD) inhibitor;
- glutathione S-transferase mu;
- and an antagonist anti-ASK1 antibody;
- and providing a multi-nutrient supplement regimen to the pregnant mammal.
Dependencies are inferred from the claim text.